|Bid||3.3000 x 2900|
|Ask||3.3800 x 1000|
|Day's Range||3.2500 - 3.3800|
|52 Week Range||2.3400 - 8.9000|
|Beta (5Y Monthly)||2.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Benzinga Pro's Stocks To Watch For Tuesday Amazon (AMZN) - An analyst at Baird issued the firm's top internet picks for 2020 Tuesday morning. Amazon was named the firm's top large-cap stock for next year; ...
Shares of Neovasc Inc. nearly tripled in active premarket trading Tuesday, after the medical device company said it submitted a premarket approval application (PMA) for its Neovasc Reducer, for the treatment of refactory angina. The company said the submission to the U.S. Food and Drug Administration includes a request for a meeting with an advisory panel. The stock shot up 162% on volume of over 400,000 shares ahead of the open, which is already nearly 10-times the full-day average about 40,600 shares. "This submission marks an important milestone in our effort to bring Reducer to the U.S. market, where it is estimated that there are up to 1.8 million patients with refractory angina," said Chief Executive Fred Colen. "These patients have traditionally had no options--they are either unsuitable for revascularization or continue to suffer with angina following revascularization procedures." The stock, on track to open at the highest price seen during regular-session hours since Jan. 22, 2019, has lost 34.8% year to date through Monday, while the S&P 500 has gained 28.5%.
Neovasc (NVCN) delivered earnings and revenue surprises of 23.77% and -41.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Neovasc (NVCN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of the Canadian medical device maker Neovasc Inc (NASDAQ: NVCN) were rallying Tuesday following the circulation of a document with a patent abstract it filed with the U.S. Patent and Trademark Office. The patent abstract pertains to the methods and apparatus for loading a prosthesis onto a delivery system. This relates to the company's Tiara prosthetic valve, which replaces the mitral valve of the heart when delivered through the apex of the heart.
Tesla Inc (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Axsome Therapeutics Inc (NASDAQ: AXSM ) Milestone Pharmaceuticals ...
The Richmond, British Columbia-based company said it had a loss of 21 cents per share. Losses, adjusted for asset impairment costs, came to 20 cents per share. The medical device company posted revenue ...
The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...